The Latin America, Middle East and Africa Blood Plasma Derivatives Market should witness market growth of 10.3% CAGR during the forecast period (2022-2028).
A rise in the number of approvals for plasma-derived products and an increase in the number of pharmaceutical manufacturing businesses are the primary drivers driving the blood plasma derivatives industry forward. Furthermore, the development of advanced and enhanced methods for preserving plasma derivatives, sophisticated fractionation procedures, and the availability of unexplored markets in emerging nations are anticipated to provide lucrative potential prospects for the market.
The therapeutic uses of blood plasma derivatives are extensive. These are used to treat a variety of life-threatening illnesses. Blood plasma derivatives are derived from the plasma of blood donors. The expansion of the market for blood plasma derivatives is fueled by the improvement and development of improved methods for preserving these blood plasma derivatives, as well as the introduction of more refined fractionation techniques.
In addition, the increasing prevalence of life-threatening disorders such as HIV, hepatitis, and hemophilia generate demand and potential in the blood plasma derivatives market. Furthermore, several government and non-government activities to organize and promote blood donation camps have resulted in a rise in the collection of human blood. This is accelerating the expansion of the market for blood plasma derivatives.
The UAE healthcare business has evolved to meet the changing needs of the people and the country's desire to become a local medical tourism hub. The COVID-19 pandemic has spurred the United Arab Emirates to recommit to healthcare investment. Since public spending contributes to more than two-thirds of overall healthcare expenditures, the government's commitment to the healthcare industry is among the key growth catalysts within the UAE's healthcare market. This factor would increase the adoption of the blood plasma derivatives market in the UAE and the growth of the regional blood plasma derivatives market would flourish in the coming years.
The Brazil market dominated the LAMEA Blood Plasma Derivatives Market by Country in 2021; thereby, achieving a market value of $1,114.2 Million by 2028. The Argentina market is anticipated to grow at a CAGR of 10.9% during (2022-2028). Additionally, The UAE would showcase a CAGR of 10.1% during (2022-2028).
Based on Application, the market is segmented into Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia, Von Willebrand's Disease, and Others. Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Type, the market is segmented into Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Biotest AG, LFB S.A., CSL Limited, Octapharma AG, Kedrion S.p.A, Sanofi S.A. and Fusion Health Care Pvt. Ltd.
A rise in the number of approvals for plasma-derived products and an increase in the number of pharmaceutical manufacturing businesses are the primary drivers driving the blood plasma derivatives industry forward. Furthermore, the development of advanced and enhanced methods for preserving plasma derivatives, sophisticated fractionation procedures, and the availability of unexplored markets in emerging nations are anticipated to provide lucrative potential prospects for the market.
The therapeutic uses of blood plasma derivatives are extensive. These are used to treat a variety of life-threatening illnesses. Blood plasma derivatives are derived from the plasma of blood donors. The expansion of the market for blood plasma derivatives is fueled by the improvement and development of improved methods for preserving these blood plasma derivatives, as well as the introduction of more refined fractionation techniques.
In addition, the increasing prevalence of life-threatening disorders such as HIV, hepatitis, and hemophilia generate demand and potential in the blood plasma derivatives market. Furthermore, several government and non-government activities to organize and promote blood donation camps have resulted in a rise in the collection of human blood. This is accelerating the expansion of the market for blood plasma derivatives.
The UAE healthcare business has evolved to meet the changing needs of the people and the country's desire to become a local medical tourism hub. The COVID-19 pandemic has spurred the United Arab Emirates to recommit to healthcare investment. Since public spending contributes to more than two-thirds of overall healthcare expenditures, the government's commitment to the healthcare industry is among the key growth catalysts within the UAE's healthcare market. This factor would increase the adoption of the blood plasma derivatives market in the UAE and the growth of the regional blood plasma derivatives market would flourish in the coming years.
The Brazil market dominated the LAMEA Blood Plasma Derivatives Market by Country in 2021; thereby, achieving a market value of $1,114.2 Million by 2028. The Argentina market is anticipated to grow at a CAGR of 10.9% during (2022-2028). Additionally, The UAE would showcase a CAGR of 10.1% during (2022-2028).
Based on Application, the market is segmented into Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia, Von Willebrand's Disease, and Others. Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Type, the market is segmented into Immunoglobulin, Albumin, Factor VIII, Factor IX, Hyperimmune Globulin, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Biotest AG, LFB S.A., CSL Limited, Octapharma AG, Kedrion S.p.A, Sanofi S.A. and Fusion Health Care Pvt. Ltd.
Scope of the Study
By Application
- Immunodeficiency Diseases
- Hypogammaglobulinemia
- Hemophilia
- Von Willebrand's Disease
- Others
By End-user
- Hospitals
- Clinics
- Others
By Type
- Immunoglobulin
- Albumin
- Factor VIII
- Factor IX
- Hyperimmune Globulin
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Biotest AG
- LFB S.A.
- CSL Limited
- Octapharma AG
- Kedrion S.p.A
- Sanofi S.A.
- Fusion Health Care Pvt. Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Blood Plasma Derivatives Market by Application
Chapter 5. LAMEA Blood Plasma Derivatives Market by End-user
Chapter 6. LAMEA Blood Plasma Derivatives Market by Type
Chapter 7. LAMEA Blood Plasma Derivatives Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Biotest AG
- LFB S.A.
- CSL Limited
- Octapharma AG
- Kedrion S.p.A
- Sanofi S.A.
- Fusion Health Care Pvt. Ltd.
Methodology
LOADING...
